ABSTRACT
The case is presented on a young Honduran female with no medical history of note, who presented with multiple areas of exudative retinal detachment (RD), and a best-corrected visual acuity of 1.3 logMAR in both eyes. She was diagnosed with incomplete Vogt-Koyanagi-Harada syndrome, and treated early with a combination of intravenous therapy with 1â¯g of prednisolone per day for 3 days, as recommended by published evidence, as well as mycophenolate mofetil (2â¯g per day). During the corticosteroids tapering, there was a recurrence of exudative retinal detachments, and megadoses of 1â¯g of intravenous corticosteroids per day were reintroduced for 6 days until the complete resolution of the fluid of the exudative RD, and cyclosporine (100â¯mg per day), subtenon triamcinolone (40â¯mg/mL), and intravitreal ranibizumab once a month in the both eyes were added to the treatment, with a great control of choroidal inflammation that resulted in the remission of symptoms and signs.
Subject(s)
Mycophenolic Acid , Uveomeningoencephalitic Syndrome , Adrenal Cortex Hormones/therapeutic use , Female , Fluorescein Angiography , Humans , Mycophenolic Acid/therapeutic use , Uveomeningoencephalitic Syndrome/drug therapy , Visual AcuityABSTRACT
Presentamos el caso de una mujer hondureña de 27 años sin antecedentes médicos de interés que presentó múltiples áreas de desprendimientos de retina (DR) exudativos y una mejor agudeza visual corregida de 1,3logMAR en ambos ojos. Fue diagnosticada de síndrome de Vogt-Koyanagi-Harada incompleto y tratada con prednisolona intravenosa (1g/24h) durante 3 días, tal y como recomienda la evidencia publicada, junto con micofenolato de mofetilo (2g/24h). Durante el descenso paulatino de corticoesteroides, los DR recidivaron, por lo que se reintrodujeron las megadosis de 1g/24h de corticoesteroides intravenosos durante 6 días hasta la resolución completa de los DR y se añadieron ciclosporina (100mg/24h), triamcinolona subtenoniana (40mg/mL) e inyecciones intravítreas mensuales de ranibizumab en ambos ojos, con un adecuado control de la inflamación coroidea que se tradujo en la remisión de los síntomas y signos (AU)
The case is presented on a young Honduran female with no medical history of note, who presented with multiple areas of exudative retinal detachment (RD), and a best-corrected visual acuity of 1.3logMAR in both eyes. She was diagnosed with incomplete Vogt-Koyanagi-Harada syndrome, and treated early with a combination of intravenous therapy with 1g of prednisolone per day for 3 days, as recommended by published evidence, as well as mycophenolate mofetil (2g per day). During the corticosteroids tapering, there was a recurrence of exudative retinal detachments, and megadoses of 1g of intravenous corticosteroids per day were reintroduced for 6 days until the complete resolution of the fluid of the exudative RD, and cyclosporine (100mg per day), subtenon triamcinolone (40mg/mL), and intravitreal ranibizumab once a month in the both eyes were added to the treatment, with a great control of choroidal inflammation that resulted in the remission of symptoms and signs (AU)
Subject(s)
Humans , Female , Adult , Uveomeningoencephalitic Syndrome/drug therapy , Mycophenolic Acid/therapeutic use , Adrenal Cortex Hormones/administration & dosage , Mycophenolic Acid/administration & dosage , Treatment Outcome , Fluorescein Angiography , Visual AcuityABSTRACT
The case is presented on a young Honduran female with no medical history of note, who presented with multiple areas of exudative retinal detachment (RD), and a best-corrected visual acuity of 1.3logMAR in both eyes. She was diagnosed with incomplete Vogt-Koyanagi-Harada syndrome, and treated early with a combination of intravenous therapy with 1g of prednisolone per day for 3 days, as recommended by published evidence, as well as mycophenolate mofetil (2g per day). During the corticosteroids tapering, there was a recurrence of exudative retinal detachments, and megadoses of 1g of intravenous corticosteroids per day were reintroduced for 6 days until the complete resolution of the fluid of the exudative RD, and cyclosporine (100mg per day), subtenon triamcinolone (40mg/mL), and intravitreal ranibizumab once a month in the both eyes were added to the treatment, with a great control of choroidal inflammation that resulted in the remission of symptoms and signs.
ABSTRACT
Un varón caucásico de 44 años con antecedentes de psoriasis en placa en tratamiento actualmente con ustekinumab se presentó con una pérdida brusca de visión en su ojo izquierdo. El examen de fondo de ojo mostró una oclusión de la vena central de la retina que coexistía con una oclusión de la arteria central de la retina. Estudios posteriores revelaron una leve policitemia, siendo la causa subyacente desconocida
A 44 year-old Caucasian male with a history of plaque psoriasis currently being treated with ustekinumab presented with sudden loss of vision in his left eye. Fundus examination showed central retinal vein occlusion coexisting with central retinal artery occlusion. Posterior examination revealed mild polycythemia, being the underlying cause unknown
Subject(s)
Humans , Male , Adult , Psoriasis/complications , Retinal Artery Occlusion/etiology , Retinal Vein Occlusion/etiology , Dermatologic Agents/therapeutic use , Psoriasis/drug therapy , Ustekinumab/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Myopia/rehabilitation , Myopia/prevention & control , Atropine/administration & dosage , Contact Lenses/adverse effectsABSTRACT
No disponible
Subject(s)
Humans , Child , Adolescent , Atropine/therapeutic use , Myopia/drug therapy , Eyeglasses , Contact Lenses , Prescriptions , Myopia/prevention & control , Visual Acuity , SunlightABSTRACT
No disponible
Subject(s)
Humans , Child , Atropine/therapeutic use , Treatment Outcome , Follow-Up Studies , Disease Progression , Refraction, Ocular , Control Groups , Ophthalmic Solutions/analysis , Ophthalmic Solutions/therapeutic useABSTRACT
Una paciente caucásica de 17 años de edad acudió a nuestro servicio con disminución de la visión; no asociaba otros síntomas en aquel momento. La exploración oftalmológica reveló hallazgos típicos de coroidopatía hipertensiva: manchas de Elschnig y estrías de Siegrist. El examen médico posterior reveló una tensión arterial de 220/155 mm Hg y se determinó que la causa subyacente de dicho trastorno era un carcinoma adrenal metastásico secretor. Este caso representa el primero descrito en el que se asocia la coroidopatía hipertensiva al carcinoma adrenal
A 17 year-old Caucasian female presented with decreased vision, with no other symptoms reported at that time. Ophthalmological examination revealed typical signs of hypertensive choroidopathy, Elschnig spots, and Siegrist streaks. Further medical examination found high blood pressure (220/155 mmHg), with a metastatic hormone-secreting adrenal carcinoma being the underlying cause of these alterations. To our knowledge, this is the first reported case of hypertensive choroidopathy associated with adrenal carcinoma
Subject(s)
Humans , Female , Adolescent , Hypertensive Retinopathy/diagnostic imaging , Hypertensive Retinopathy/etiology , Choroid Diseases/etiology , Choroid Diseases/diagnostic imaging , Adrenal Cortex Neoplasms/complications , Adrenocortical Carcinoma/complications , Tomography, X-Ray Computed , Fluorescein Angiography , Fatal OutcomeABSTRACT
A 17 year-old Caucasian female presented with decreased vision, with no other symptoms reported at that time. Ophthalmological examination revealed typical signs of hypertensive choroidopathy, Elschnig spots, and Siegrist streaks. Further medical examination found high blood pressure (220/155mmHg), with a metastatic hormone-secreting adrenal carcinoma being the underlying cause of these alterations. To our knowledge, this is the first reported case of hypertensive choroidopathy associated with adrenal carcinoma.
Subject(s)
Adrenal Gland Neoplasms/complications , Carcinoma/complications , Choroid Diseases/etiology , Hypertension/complications , Adolescent , Adrenal Gland Neoplasms/metabolism , Carcinoma/metabolism , Choroid Diseases/diagnostic imaging , Fatal Outcome , Female , Humans , Papilledema/diagnostic imaging , Papilledema/etiologyABSTRACT
A 44 year-old Caucasian male with a history of plaque psoriasis currently being treated with ustekinumab presented with sudden loss of vision in his left eye. Fundus examination showed central retinal vein occlusion coexisting with central retinal artery occlusion. Posterior examination revealed mild polycythemia, being the underlying cause unknown.
Subject(s)
Psoriasis/complications , Retinal Artery Occlusion/etiology , Retinal Vein Occlusion/etiology , Adult , Dermatologic Agents/therapeutic use , Humans , Male , Psoriasis/drug therapy , Retinal Artery Occlusion/complications , Retinal Vein Occlusion/complications , Ustekinumab/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Myopia/epidemiology , Visual Acuity , Retinal Detachment/complications , Risk Factors , Eyeglasses/trends , Hyperopia/epidemiology , Myopia/complications , Myopia/economics , Macular Degeneration/complications , Disease ProgressionSubject(s)
Myopia/therapy , Adolescent , Adult , Age of Onset , Atropine/therapeutic use , Child , Contact Lenses , Disease Progression , Eyeglasses , Humans , Incidence , Life Style , Lighting , Morbidity/trends , Myopia/epidemiology , Myopia/etiology , Myopia/prevention & control , Ophthalmic Solutions , Risk Factors , SunlightABSTRACT
OBJETIVO: Confirmar la seguridad y eficacia de la aplicación diaria nocturna de atropina superdiluida al 0,01% en colirio para frenar la progresión de la miopía en los niños. MATERIAL Y MÉTODOS: Un total de 200 niños de 9-12 años randomizados en el grupo tratado y control sin tratamiento. Se realizó refracción bajo cicloplejia. RESULTADOS: La progresión miópica del grupo tratado fue de -0,14 ± 0,35 frente a -0,65 ± 0,54 en el grupo control, sin tratamiento. La obligación de suspender el tratamiento por efectos secundarios fue solo del 2% de los casos. CONCLUSIÓN: La atropina superdiluida (0,01%) en colirio es eficaz y bien tolerada, reduciendo a la cuarta parte la progresión de la miopía
OBJECTIVE: To confirm the clinical security and effectiveness of the daily application of 0.01% superdiluted atropine eyedrops in the progression of myopia in children. MATERIAL AND METHODS: A total of 200 children 9-12 years of age were randomised into a treated group and a control without treatment. Refraction under cycloplegia was performed. RESULTS: Myopia progression of the treated group was -0.14 ± 0.35 versus -0.65 ± 0.54 in the control group without treatment. Only 2% of patients were forced to stop treatment due to side effects. CONCLUSION: Atropine superdiluted atropine 0.01% eyedrops is effective and well tolerated, and reduced myopia progression by 25%
Subject(s)
Humans , Male , Female , Child , Myopia/drug therapy , Atropine/therapeutic use , Treatment Outcome , Ophthalmic Solutions/therapeutic use , Long-Term Care/trends , Refraction, Ocular , Prospective Studies , Analysis of VarianceABSTRACT
OBJECTIVE: To confirm the clinical security and effectiveness of the daily application of 0.01% superdiluted atropine eyedrops in the progression of myopia in children. MATERIAL AND METHODS: A total of 200 children 9-12 years of age were randomised into a treated group and a control without treatment. Refraction under cycloplegia was performed. RESULTS: Myopia progression of the treated group was -0.14±0.35 versus -0.65±0.54 in the control group without treatment. Only 2% of patients were forced to stop treatment due to side effects. CONCLUSION: Atropine superdiluted atropine 0.01% eyedrops is effective and well tolerated, and reduced myopia progression by 25%.
Subject(s)
Atropine/administration & dosage , Muscarinic Antagonists/administration & dosage , Myopia/prevention & control , Adolescent , Atropine/adverse effects , Child , Disease Progression , Female , Humans , Male , Muscarinic Antagonists/adverse effects , Ophthalmic Solutions , Prospective Studies , Time Factors , Treatment OutcomeABSTRACT
OBJETIVO: Evaluar la eficacia de las terapias intravítreas en casos de degeneración macular asociada a la edad (DMAE) atrófica con fluido intra- o subretiniano. MÉTODOS: Revisamos, de forma retrospectiva, las características de pacientes diagnosticados de DMAE atrófica con fluido intra- o subretiniano. Examinamos las retinografías y las imágenes de tomografía de coherencia óptica de dominio espectral analizando en ellas la presencia de fluido y su densidad. Descartamos la existencia de neovascularización coroidea mediante angiografía con fluoresceína o con verde de indocianina. RESULTADOS: Se incluyeron 14 ojos de 13 pacientes con una edad media de 72,64 años y un seguimiento medio de 80,5 semanas. Se observó fluido intrarretiniano en 6 ojos (42,9%) y fluido subretiniano en 8 ojos (57,1%). Este fluido era de alta densidad en 4 de ellos (28,5%) y de baja densidad en los otros 4 ojos (28,5%). La mejor agudeza visual corregida evaluada mediante la escala de Snellen mejoró de 0,37 inicialmente a 0,56 en la visita final (p = 0,002). El grosor macular central (en micras) disminuyó de forma significativa de 291,0 μm al inicio a 228,9μm en la visita final (p≤0,001). Del total, 8 ojos recibieron ranibizumab, 5 ojos recibieron bevacizumab y un ojo recibió triamcinolona intravítrea. CONCLUSIONES: La DMAE atrófica puede presentarse con fluido intra- o subretiniano en ausencia de neovascularización coroidea. Son necesarios estudios adicionales para analizar el valor de estos hallazgos como factor de riesgo en el desarrollo de formas avanzadas de DMAE, así como la eficacia de las terapias intravítreas
OBJECTIVE: To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid. METHODS: A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography. RESULTS: The study included 14 eyes from 13 patients with a mean age of 72.64 years and a mean follow-up of 80.5 weeks. Intraretinal fluid was observed in 6 eyes (42.9%), while subretinal fluid was shown in 8 eyes (57.1%), with high density in 4 eyes (28.5%), and low density in 4 eyes (28.5%). Snellen best-corrected visual acuity improved from 0.37 at baseline to 0.56 at the final visit (P=.002). Central subfield thickness (microns) significantly decreased (P<.001) from 291.0 at baseline to 228.9 at the final visit. Eight eyes received ranibizumab, 5 eyes received bevacizumab, and one case received triamcinolone. CONCLUSIONS: Cases of atrophic AMD may present with subretinal or intraretinal fluid in the absence Neovascularisation. Further studies are required to analyse the value of this finding as a risk factor of developing advanced forms of AMD, as well as the efficacy of intravitreal therapies
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Macular Degeneration/drug therapy , Macular Degeneration/surgery , Macular Degeneration , Ranibizumab/therapeutic use , Bevacizumab/therapeutic use , Triamcinolone/therapeutic use , Tomography, Optical Coherence/instrumentation , Fluorescein Angiography/instrumentation , Tomography, Optical Coherence/standards , Tomography, Optical Coherence , Retrospective Studies , Treatment Outcome , Visual Acuity/physiology , Intravitreal Injections/instrumentation , Intravitreal Injections/methods , Tomography, Optical Coherence/methodsABSTRACT
OBJECTIVE: To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid. METHODS: A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography. RESULTS: The study included 14 eyes from 13 patients with a mean age of 72.64 years and a mean follow-up of 80.5 weeks. Intraretinal fluid was observed in 6 eyes (42.9%), while subretinal fluid was shown in 8 eyes (57.1%), with high density in 4 eyes (28.5%), and low density in 4 eyes (28.5%). Snellen best-corrected visual acuity improved from 0.37 at baseline to 0.56 at the final visit (P=.002). Central subfield thickness (microns) significantly decreased (P<.001) from 291.0 at baseline to 228.9 at the final visit. Eight eyes received ranibizumab, 5eyes received bevacizumab, and one case received triamcinolone. CONCLUSIONS: Cases of atrophic AMD may present with subretinal or intraretinal fluid in the absence Neovascularisation. Further studies are required to analyse the value of this finding as a risk factor of developing advanced forms of AMD, as well as the efficacy of intravitreal therapies.
Subject(s)
Bevacizumab/administration & dosage , Ranibizumab/administration & dosage , Wet Macular Degeneration/drug therapy , Aged , Aged, 80 and over , Angiogenesis Inhibitors/therapeutic use , Bevacizumab/therapeutic use , Exudates and Transudates , Female , Fluorescein Angiography , Humans , Intravitreal Injections , Male , Ranibizumab/therapeutic use , Retina/pathology , Retinal Drusen/etiology , Subretinal Fluid/drug effects , Tomography, Optical Coherence , Treatment Outcome , Triamcinolone/administration & dosage , Triamcinolone/therapeutic use , Wet Macular Degeneration/pathologyABSTRACT
No disponible
